
    
      Twelve (12) SPMS subjects will be enrolled in this study in two dose cohorts. Each subject
      will receive SCM- 010 by intrathecal (IT) administration at baseline and will be followed up
      for 24 weeks for efficacy and 48 weeks for safety.
    
  